MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement

November 7, 2022

The study is being conducted in the U.S. and financed by MedinCell’s partner, Arthritis Innovation Corporation (AIC) 

F14 (mdc-CWM) is a sustained-release formulation of the non-steroidal anti-inflammatory drug (NSAID), celecoxib, administered intraarticularly at the end of Total Knee Replacement surgery (TKR) 

The investigational product aims to facilitate patient recovery by providing post-operative pain relief for weeks and accelerating improvement in knee function, and potentially decreasing the need for addictive opioids 

The 150-patient, multicenter, randomized, double blind Phase 3 safety and efficacy trial was designed in consultation with the U.S. FDA 

F14 (mdc-CWM) is the third product using MedinCell’s proprietary technology BEPO® to reach or to have completed a Phase 3 clinical trial 

Session en français

Rendez-vous le mardi 12 septembre à 18h00 pour la diffusion en direct de l'Assemblée Générale mixte

English session

On Tuesday September 12 at 6:00 p.m. live of the Combined General Meeting (in French)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.